Developer docs
API playgroundTry for free, no card

Search company profiles

Flynn Pharma

Full company profile

uuid000mwen

Namestring
Flynn Pharma
Legal namestring
Flynn Pharma Limited
Websiteurl
flynnpharma.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Flynn Pharma is a privately held pharmaceutical company founded in 1994 and headquartered in Stevenage, England. The company develops, supplies, and distributes branded and generic medicines across six therapy areas: psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Its core commercial thesis is to re-discover and re-energise established drugs — introducing new products, improving existing formulations, and adding new indications to extend the value of its portfolio. Geographic operations span the United Kingdom and the Republic of Ireland, with a wholly owned German subsidiary (Inresa) and a UK affiliate (MicroPharm) forming the broader corporate family.

The company sells primarily through UK-based Contract Sales Organisations (CSOs) that engage NHS clinicians, pharmacists, and prescribers, with products distributed via pharmacy and dispensing channels. Flynn Pharma also operates an in-licensing proposition for companies seeking entry into the UK or EU pharmaceutical markets, offering branded campaign capabilities across primary care, secondary care, and specialist medicine. Its principal digital asset is the Flynn Forum platform — a healthcare-professional-only site hosting CPD-certified events, clinical tools, education, and patient support materials segmented into three communities: Neurodevelopmental Disorders, Women's Health, and General Medicine. The business is privately held with no parent company, no disclosed institutional investors, and no publicly filed revenue data.

Short descriptiontext

Flynn Pharma is a privately held UK pharmaceutical company, founded 1994, that supplies branded and generic medicines across psychiatry, paediatrics, women's health, gastroenterology, anti-infective, and emergency medicine to the UK and Irish healthcare markets via CSO-led sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded pharmaceuticals, generic medicines, prescription drug supply, women's health therapeutics, neurodevelopmental disorder drugs
Industry3 codes
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Products (Branded and Generic Medicines)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Flynn Pharma generates revenue through the sale of branded and generic medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine. The company introduces new products, improves existing formulations, and adds new indications to their product portfolio.

flynnpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Flynn Pharma develops, supplies, and distributes branded and generic pharmaceutical medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. The company re-discovers and re-energises established drugs, introduces new products, improves existing formulations, and adds new indications. It also operates the Flynn Forum platform, a dedicated digital resource for UK healthcare professionals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Flynn Pharma is a privately held pharmaceutical company engaged in developing, introducing, and supplying branded and generic medicines. The company operates across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Flynn Pharma's core digital product is the Flynn Forum platform, which comprises three distinct community sub-brands (NDD Community, Women's Health Community, and General Medicine Community) providing therapy-specific resources, events, and product information for UK healthcare professionals. The company also maintains external product listings for its medicines across the UK and Republic of Ireland markets.

Product and service4 records
1Flynn Forum
CategoryHealthcare Professional Education Platform
Description

A digital platform for UK healthcare professionals hosting education, training, resources, events, and product information across neurodevelopmental disorders (NDD), women's health, and general medicine. The platform contains clinical tools and patient support materials to help with consultations in each community.

2Flynn Pharma Medicines (United Kingdom)
CategoryPharmaceutical Products
Description

Flynn Pharma's portfolio of branded and generic medicines supplied in the UK market, covering therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine.

3Flynn Pharma Medicines (Republic of Ireland)
CategoryPharmaceutical Products
Description

Flynn Pharma's portfolio of branded and generic medicines supplied in the Republic of Ireland market, covering the same multi-therapy area range as the UK portfolio.

4Pharmaceutical In-Licensing Partnerships (UK/EU)
CategoryPharmaceutical Commercialisation Services
Description

An in-licensing partnership offering for pharmaceutical companies seeking to enter the UK or EU markets, providing Flynn Pharma's regulatory infrastructure, sales capabilities, and branded campaign execution across key therapy areas.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Flynn Pharma operates as a dynamic and responsible in-licensing partner for companies interested in successfully entering the UK or EU pharmaceutical markets. They have significant experience and capability in creating and implementing compelling branded campaigns that deliver industry leading results in key therapy areas. Their commitment to collaboration enables delivery of value to patients, healthcare professionals and partners across primary care, secondary care, and specialist medicine.

Strategic tierMinorTypeOthers
Description

Member of the Flynn Pharma family of companies. MicroPharm is listed as another group company alongside Flynn Pharma.

Strategic tierMinorTypeOthers
Description

Member of the Flynn Pharma family of companies. Inresa is based in Germany and listed as another group company alongside Flynn Pharma.

4NHS Leaders and Third Sector Organisations
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Flynn Pharma develops patient-focused resources and materials designed to improve decision-making and support service improvement across multiple therapy areas. These are developed in collaboration with clinicians, NHS leaders and the third sector.

flynnpharma.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global generics and specialty pharma with established European branded-generic operations — comparable as a broader incumbent operating Flynn's same commercial model at much larger scale across multiple regions.

TypeBroad incumbent
Description

US-headquartered but with growing European footprint, focused on affordable generics and specialty branded products across CNS, women's health and other therapy areas overlapping with Flynn.

TypeDirect peer
Description

Women's-health focused specialty pharma with a UK and European footprint, addressing menopause, contraception and similar indications that overlap directly with Flynn's Women's Health Community portfolio.

TypeEmerging player
Description

Smaller specialty pharma focused on women's health and niche indications with European distribution, comparable to Flynn's therapeutic-area focus but at a smaller scale and different geographic centre of gravity.

5Alliance Pharma plc
TypeDirect peer
Description

UK-listed specialty pharma that acquires, markets and distributes established branded prescription and consumer healthcare products across multiple therapy areas — closely matching Flynn's branded/generic re-energisation model and UK/European distribution focus.

TypeDirect peer
Description

Privately held UK and Ireland pharma company marketing branded generic and specialty medicines across women's health, CNS, and other therapy areas — directly comparable in scale, geography, and therapy mix to Flynn Pharma.

TypeBroad incumbent
Description

World's largest generic medicines manufacturer with a deep UK/European presence, supplying many of the same pharmacy and NHS channels that Flynn targets — a broader incumbent competing in the same distribution layer.

TypeBroad incumbent
Description

Global generics and branded pharma with major UK operations, competing for the same NHS tenders and pharmacy distribution slots that Flynn depends on for revenue.

TypeDirect peer
Description

Northern Ireland-headquartered pharma focused on branded generics and established molecules across women's health, pain and CNS — operating in similar UK/Irish markets with a comparable branded-generic commercialisation model.

TypeBroad incumbent
Description

European generics and specialty pharma headquartered in Prague with strong UK/Ireland distribution — overlapping with Flynn in branded-generic distribution to pharmacies and NHS customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flynn Pharma

Pharmaceutical Products (Branded and Generic Medicines)flynnpharma.com

Flynn Pharma is a privately held UK pharmaceutical company, founded 1994, that supplies branded and generic medicines across psychiatry, paediatrics, women's health, gastroenterology, anti-infective, and emergency medicine to the UK and Irish healthcare markets via CSO-led sales.

What Flynn Pharma does

Flynn Pharma is a privately held pharmaceutical company founded in 1994 and headquartered in Stevenage, England. The company develops, supplies, and distributes branded and generic medicines across six therapy areas: psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Its core commercial thesis is to re-discover and re-energise established drugs — introducing new products, improving existing formulations, and adding new indications to extend the value of its portfolio. Geographic operations span the United Kingdom and the Republic of Ireland, with a wholly owned German subsidiary (Inresa) and a UK affiliate (MicroPharm) forming the broader corporate family.

The company sells primarily through UK-based Contract Sales Organisations (CSOs) that engage NHS clinicians, pharmacists, and prescribers, with products distributed via pharmacy and dispensing channels. Flynn Pharma also operates an in-licensing proposition for companies seeking entry into the UK or EU pharmaceutical markets, offering branded campaign capabilities across primary care, secondary care, and specialist medicine. Its principal digital asset is the Flynn Forum platform — a healthcare-professional-only site hosting CPD-certified events, clinical tools, education, and patient support materials segmented into three communities: Neurodevelopmental Disorders, Women's Health, and General Medicine. The business is privately held with no parent company, no disclosed institutional investors, and no publicly filed revenue data.

Flynn Pharma firmographics

Firmographics
Name
Flynn Pharma
Legal name
Flynn Pharma Limited
Website
https://flynnpharma.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
11–50 employees
Short description
Flynn Pharma is a privately held UK pharmaceutical company, founded 1994, that supplies branded and generic medicines across psychiatry, paediatrics, women's health, gastroenterology, anti-infective, and emergency medicine to the UK and Irish healthcare markets via CSO-led sales.
Ownership category
akta.pro rank

Flynn Pharma industry classification

Industry
Product category
Pharmaceutical Products (Branded and Generic Medicines)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAN
Women’s Health & Reproductive Specialty Pharmaceuticals

Keywords

  • Branded pharmaceuticals
  • Generic medicines
  • Prescription drug supply
  • Women's health therapeutics
  • Neurodevelopmental disorder drugs

Where Flynn Pharma is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Flynn Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: Flynn Pharma generates revenue through the sale of branded and generic medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine. The company introduces new products, improves existing formulations, and adds new indications to their product portfolio.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Flynn Pharma product offering

Product offering

Core offering

Flynn Pharma develops, supplies, and distributes branded and generic pharmaceutical medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. The company re-discovers and re-energises established drugs, introduces new products, improves existing formulations, and adds new indications. It also operates the Flynn Forum platform, a dedicated digital resource for UK healthcare professionals.

Product overview

Flynn Pharma is a privately held pharmaceutical company engaged in developing, introducing, and supplying branded and generic medicines. The company operates across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. Flynn Pharma's core digital product is the Flynn Forum platform, which comprises three distinct community sub-brands (NDD Community, Women's Health Community, and General Medicine Community) providing therapy-specific resources, events, and product information for UK healthcare professionals. The company also maintains external product listings for its medicines across the UK and Republic of Ireland markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flynn Forum A digital platform for UK healthcare professionals hosting education, training, resources, events, and product information across neurodevelopmental disorders (NDD), women's health, and general medicine. The platform contains clinical tools and patient support materials to help with consultations in each community.
  • Flynn Pharma Medicines (United Kingdom) Flynn Pharma's portfolio of branded and generic medicines supplied in the UK market, covering therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology and emergency medicine.
  • Flynn Pharma Medicines (Republic of Ireland) Flynn Pharma's portfolio of branded and generic medicines supplied in the Republic of Ireland market, covering the same multi-therapy area range as the UK portfolio.
  • Pharmaceutical In-Licensing Partnerships (UK/EU) An in-licensing partnership offering for pharmaceutical companies seeking to enter the UK or EU markets, providing Flynn Pharma's regulatory infrastructure, sales capabilities, and branded campaign execution across key therapy areas.

Companies that use Flynn Pharma

Customer profile

Segments2 records

Ideal customer profiles3 records

Flynn Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Flynn Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Companies seeking UK/EU market entrycoreStrategic or Co-development PartnerFlynn Pharma operates as a dynamic and responsible in-licensing partner for companies interested in successfully entering the UK or EU pharmaceutical markets. They have significant experience and capability in creating and implementing compelling branded campaigns that deliver industry leading results in key therapy areas. Their commitment to collaboration enables delivery of value to patients, healthcare professionals and partners across primary care, secondary care, and specialist medicine.
  • MicroPharmminorOthersMember of the Flynn Pharma family of companies. MicroPharm is listed as another group company alongside Flynn Pharma.
  • InresaminorOthersMember of the Flynn Pharma family of companies. Inresa is based in Germany and listed as another group company alongside Flynn Pharma.
  • NHS Leaders and Third Sector OrganisationsminorStrategic or Co-development PartnerFlynn Pharma develops patient-focused resources and materials designed to improve decision-making and support service improvement across multiple therapy areas. These are developed in collaboration with clinicians, NHS leaders and the third sector.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Flynn Pharma competitors and assessment

Company assessment

Broad incumbents

  • Aspen Pharmacare Holdings: Global generics and specialty pharma with established European branded-generic operations — comparable as a broader incumbent operating Flynn's same commercial model at much larger scale across multiple regions.
  • Amneal Pharmaceuticals: US-headquartered but with growing European footprint, focused on affordable generics and specialty branded products across CNS, women's health and other therapy areas overlapping with Flynn.
  • Teva Pharmaceutical Industries: World's largest generic medicines manufacturer with a deep UK/European presence, supplying many of the same pharmacy and NHS channels that Flynn targets — a broader incumbent competing in the same distribution layer.
  • Viatris (formerly Mylan): Global generics and branded pharma with major UK operations, competing for the same NHS tenders and pharmacy distribution slots that Flynn depends on for revenue.
  • Zentiva Group: European generics and specialty pharma headquartered in Prague with strong UK/Ireland distribution — overlapping with Flynn in branded-generic distribution to pharmacies and NHS customers.

Direct peers

  • Theramex: Women's-health focused specialty pharma with a UK and European footprint, addressing menopause, contraception and similar indications that overlap directly with Flynn's Women's Health Community portfolio.
  • Alliance Pharma plc: UK-listed specialty pharma that acquires, markets and distributes established branded prescription and consumer healthcare products across multiple therapy areas — closely matching Flynn's branded/generic re-energisation model and UK/European distribution focus.
  • Consilient Health: Privately held UK and Ireland pharma company marketing branded generic and specialty medicines across women's health, CNS, and other therapy areas — directly comparable in scale, geography, and therapy mix to Flynn Pharma.
  • Galen (Galen Limited): Northern Ireland-headquartered pharma focused on branded generics and established molecules across women's health, pain and CNS — operating in similar UK/Irish markets with a comparable branded-generic commercialisation model.

Emerging players

  • Stragen Pharma: Smaller specialty pharma focused on women's health and niche indications with European distribution, comparable to Flynn's therapeutic-area focus but at a smaller scale and different geographic centre of gravity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Flynn Pharma social profiles

Digital presence

Flynn Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flynn Pharma leadership team

Management profile

Number of profiles

Flynn Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Flynn Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flynn Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flynn Pharma

What does Flynn Pharma do?

Flynn Pharma develops, supplies, and distributes branded and generic pharmaceutical medicines across multiple therapy areas including psychiatry, paediatrics, anti-infective medicine, women's health, gastroenterology, and emergency medicine. The company re-discovers and re-energises established drugs, introduces new products, improves existing formulations, and adds new indications. It also operates the Flynn Forum platform, a dedicated digital resource for UK healthcare professionals.

Is Flynn Pharma a public or private company?

Flynn Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Flynn Pharma founded?

Flynn Pharma was founded in 1994. It employs 11 to 50 people.

Where is Flynn Pharma based?

Flynn Pharma is headquartered in Stevenage, United Kingdom, in the Europe region.

How does Flynn Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Flynn Pharma's main competitors?

Broad incumbents on record are Aspen Pharmacare Holdings, Amneal Pharmaceuticals, Teva Pharmaceutical Industries, Viatris (formerly Mylan) and Zentiva Group. Direct peers are Theramex, Alliance Pharma plc, Consilient Health and Galen (Galen Limited). Stragen Pharma is listed as an emerging player.

Does Flynn Pharma have an API?

No public API is recorded for Flynn Pharma.

What industry is Flynn Pharma in?

Flynn Pharma's product category is Pharmaceutical Products (Branded and Generic Medicines). Its primary akta.pro industry code is HLAIAJAA, Full-Line Pharmaceutical Wholesalers, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsCourt Overrules Tribunal on CMA Phenytoin DecisionThe UK Court of Appeal has ruled that the Competition Appeal Tribunal was wrong to set aside the CMA's 2022 decision finding that Pfizer and Flynn Pharma abused their dominant positions by charging excessive prices for phenytoin sodium capsules, an epilepsy drug, between 2012 and 2016. The Court upheld the CMA's appeal, finding the CAT misread and mischaracterised the CMA's decision on critical issues and wrongly concluded the CMA had demonstrated bias in its analysis. The Court has rejected both Pfizer and Flynn's appeals and will now consider submissions on whether to reinstate the CMA's original fines totalling approximately £70 million.Law360Appeals Court Scraps Redo Of Pfizer, Flynn Drug FinesThe Court of Appeal ruled on Friday that the Competition Appeal Tribunal was wrong to remake a decision to fine Pfizer Ltd. and Flynn Pharma Ltd. £70 million ($93 million) for excessive pricing, finding the process tainted by procedural unfairness.PR NewswireNeurim Pharmaceuticals' New Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Flynn Pharma in UK and IrelandNeurim Pharmaceuticals and Flynn Pharma announced a license agreement granting Flynn exclusive marketing rights for Neurim's pediatric prolonged-release melatonin (PedPRM) in the UK and Ireland. PedPRM, designed to treat sleep disorders in children with autism spectrum disorders and neurogenetic diseases, completed Phase III trials demonstrating statistically significant improvements in total sleep time. This expands an existing partnership, as Flynn has been marketing Neurim's adult insomnia drug Circadin in these markets since 2012.